Skip to main content
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. — Investor Relations & Filings

Ticker · CRDF ISIN · US14147L1089 LEI · 549300AHOLZBHHYFWP04 US Professional, scientific and technical activities
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2026-06-03 Investor Presentation
Country US United States of America
Listing US CRDF

About Cardiff Oncology, Inc.

https://cardiffoncology.com/

Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel cancer therapies. The company's primary focus is on leveraging the inhibition of Polo-like kinase 1 (PLK1), a well-validated oncology drug target. Its lead drug candidate, onvansertib, is an oral PLK1 inhibitor being evaluated in clinical trials. These programs test onvansertib in combination with standard-of-care therapeutics for various cancer indications. The company's strategy is designed to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Investor Presentation Classification · 90% confidence The document is a Current Report on Form 8-K, Item 7.01, which discloses and furnishes an investor presentation (Exhibit 99.1) reviewing Phase 2 data and study plans. This matches the description of an Investor Presentation rather than a full financial report or mere regulatory notice.
2026-06-03 English
8-K
Legal Proceedings Report Classification · 84% confidence The document is an SEC Form 8-K “Current Report” under the Exchange Act, specifically disclosing the company’s lawsuit and the counterparty’s termination of a material licensing agreement—a legal dispute update. This fits the definition of a Legal Proceedings Report. There is no category for Form 8-K itself, so the best match is LTR (updates on significant lawsuits/legal matters).
2026-05-29 English
8-K
Legal Proceedings Report Classification · 92% confidence The document is a Form 8‐K “Current Report” filed with the SEC under Item 8.01 “Other Events,” primarily disclosing that the company has filed a lawsuit and detailing the legal dispute. It is not a financial or earnings report, an annual/quarterly statement, or a simple notification of report publication. It is an update on significant litigation and thus fits the Legal Proceedings Report category.
2026-05-19 English
8-K
Earnings Release Classification · 90% confidence The document is a Form 8-K current report under the Securities Exchange Act, specifically Item 2.02 “Results of Operations and Financial Condition,” which furnishes a press release announcing first-quarter financial results. This is exactly the type of “initial announcement of quarterly/periodical financial results” described by the Earnings Release category. Therefore, it should be classified as an Earnings Release (ER). Q1 2026
2026-05-14 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated April 6, 2026. The content focuses on the appointment of new senior officers: Chief Financial Officer, Chief Operating Officer, and President/CEO, including details about their compensation and stock options. There is no financial data or earnings information presented. The primary subject is changes in senior management. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document is not a full annual or quarterly report, nor is it an earnings release or other category. Therefore, the correct classification is MANG with high confidence.
2026-04-09 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.